Who should not take GLP-1 medications?

Other situations require a different answer. Pregnancy, severe stomach-emptying problems, previous pancreatitis, and certain medication combinations may mean treatment should be avoided, delayed, or managed differently. Kidney disease, diabetes-related eye disease, and common thyroid conditions do not automatically disqualify everyone.

The key distinction is between a contraindication, which means a particular medicine should not be used, and a precaution, which requires an individual assessment. The exact drug, formulation, reason for treatment, and your health history determine which applies.

Which medicines does this guidance cover?

“GLP-1” is often used as shorthand for several prescription medicines. GLP-1 stands for glucagon-like peptide-1, a hormone involved in blood sugar regulation, appetite, and digestion. GLP-1 receptor agonists act on the receptors that respond to this hormone.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts at both GIP and GLP-1 receptors, so it is technically a dual-action medicine, although people often include it in GLP-1 discussions.

This article focuses primarily on these commonly discussed weight-management treatments:

Helimeds provides separate treatment information for injectable Wegovy.

Ozempic also contains semaglutide, and Mounjaro contains tirzepatide. Those names are not substitutes for Wegovy and Zepbound: their approved uses and prescribing instructions are not identical.

There is no single exclusion list that can safely replace the instructions for every GLP-1 medicine. When reviewing GLP-1 eligibility, start with the exact product name and route, rather than assuming that advice about one injection applies to another medicine or a tablet.

Who should not take Wegovy or Zepbound?

People with medullary thyroid carcinoma or MEN 2

Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors. These tumors occurred in animal studies; it is not known whether the medicines cause them in humans. The warning does not establish that these drugs cause every type of thyroid cancer.

Both products are contraindicated for people who have:

• A personal history of medullary thyroid carcinoma, often shortened to MTC.
• A family history of MTC.
• Multiple endocrine neoplasia syndrome type 2, called MEN 2, an inherited condition associated with certain endocrine tumors.

These restrictions are described in the Wegovy prescribing information and Zepbound prescribing information.

“Thyroid cancer runs in my family” is important information, but the type matters. If possible, find out the relative’s exact diagnosis or bring available medical records. Do not guess that it was harmless or assume that every thyroid cancer is medullary thyroid carcinoma.

Hypothyroidism, Hashimoto’s disease, and taking thyroid replacement medicine are not the same as MTC or MEN 2. They still belong in your medical history, particularly when reviewing other medicines, but they do not establish this specific contraindication.

A new neck lump, persistent hoarseness, or trouble swallowing warrants medical evaluation. A symptom alone does not diagnose thyroid cancer, and it should not be assessed solely through a medication eligibility questionnaire.

People with a serious allergy to the specific product

A previous serious allergic reaction to semaglutide, tirzepatide, or an ingredient in the intended product can make that product unsafe to use. The ingredient list matters because different preparations may contain different inactive ingredients.

Tell the clinician what actually happened: whether there was swelling, difficulty breathing, widespread hives, fainting, emergency treatment, or another reaction. Bring the medicine’s name and any available treatment records.

Nausea after an injection is different from a serious allergy. Both deserve attention, but labeling every unpleasant symptom an “allergy” can obscure what happened and complicate future treatment choices.

A serious reaction to one medicine also does not prove that another related medicine is safe. Do not test a replacement on your own; the prescriber needs to assess the previous reaction and the proposed alternative.

Helimeds' important safety information describes platform responsibilities and compounded-medication qualifications; it does not replace the exact product label.

A firm contraindication is different from a condition that can sometimes be managed with monitoring. Knowing which one applies changes the treatment decision.

When pregnancy or feeding plans change the answer

Pregnancy and planning to conceive

GLP-1-based treatment for weight loss is not appropriate during pregnancy. Intentional weight loss offers no benefit during pregnancy, and medication exposure raises product-specific safety concerns.

If you are pregnant, think you may be pregnant, or are planning pregnancy, contact the prescribing clinician promptly. The next step depends partly on whether the medicine is being used for weight management, diabetes, or another approved purpose. Someone who needs blood sugar treatment also needs a plan to maintain appropriate glucose control.

Pregnancy planning should happen before trying to conceive. Some medicines remain in the body after the last dose, so the clinician needs to use the exact product’s guidance to determine when treatment should end. Do not borrow a stopping interval from a different drug or assume that missing one dose removes exposure.

Bring your intended pregnancy timeline, the product name, the formulation, and the date of your most recent dose. These details make a conversation about GLP-1 medicines and pregnancy more useful than a general question about whether “weight-loss shots” are safe.

Breastfeeding and oral contraception need separate decisions

Breastfeeding should not be grouped automatically with pregnancy as though the evidence and instructions were identical. The medicine, oral versus injectable formulation, available milk-exposure information, and the infant’s circumstances all matter.

A clinician can help weigh the need for treatment against the available safety information and feeding plans. Do not assume that advice for injectable semaglutide applies to oral semaglutide, or that findings about semaglutide answer questions about tirzepatide.

Tirzepatide also has a specific interaction with oral hormonal contraception. If you use a birth control pill and are considering Zepbound, resolve the contraception plan before starting treatment. Ask the clinician or pharmacist to confirm the labeled advice about a non-oral method or additional barrier protection, including the required period after starting treatment and after dose increases.

This interaction is not a reason to assume that all contraception fails with GLP-1 medicines. It is a reason to identify the exact medication and contraceptive method rather than relying on class-wide advice.

Which health conditions require extra assessment?

Many online exclusion lists mix firm contraindications with conditions that call for caution. That can unnecessarily discourage people who might benefit from treatment, while giving others false reassurance that an unlisted condition is irrelevant.

For Wegovy or Zepbound, the following histories deserve a focused conversation. They do not all have the same implications.

Severe gastroparesis and ongoing digestive symptoms

Gastroparesis means that the stomach empties too slowly without a blockage explaining the delay. GLP-1-based medicines can slow stomach emptying, which makes an existing stomach-emptying disorder particularly relevant.

Wegovy and Zepbound are generally not recommended for people with severe gastroparesis. This is different from saying that anyone with occasional heartburn, constipation, or nausea cannot use them.

Report frequent vomiting, prolonged fullness after small meals, difficulty maintaining food intake, or a previous gastroparesis diagnosis. The clinician may need to investigate the symptoms before considering appetite-suppressing treatment.

Previous stomach or intestinal surgery also belongs in the assessment. The practical question is whether treatment could worsen existing symptoms, interfere with nutrition, or make an underlying problem harder to recognize. Managing GLP-1 digestive side effects is a separate question from determining whether a serious digestive disorder makes treatment unsuitable.

Previous pancreatitis or gallbladder disease

Pancreatitis is inflammation of the pancreas. A previous episode is important, but it should not be described as a universal, automatic contraindication to every GLP-1 medicine.

The clinician needs to know when it happened, the suspected cause, whether it recurred, and whether you have ongoing symptoms. Records can help distinguish confirmed pancreatitis from an episode of unexplained abdominal pain.

Gallstones and gallbladder inflammation also matter. A history of gallstones does not automatically settle the decision, but current symptoms may require evaluation before treatment begins.

For both conditions, identify the previous diagnosis rather than reporting only “stomach trouble.” Pancreatic and gallbladder problems can require different investigations and treatment, even when both cause upper abdominal pain.

For a surgery-specific discussion, see our guide to GLP-1 treatment after gallbladder removal.

Kidney disease or vulnerability to dehydration

Kidney disease is not a blanket reason to reject all GLP-1 treatment. The exact medicine and the person’s kidney function matter.

One practical concern is dehydration. Vomiting, diarrhea, and reduced fluid intake can contribute to kidney injury. Someone with existing kidney disease or medicines that affect fluid balance may need closer assessment and a clear plan for illness.

Tell the clinician about previous kidney injury, dialysis, fluid restrictions, and any difficulty staying hydrated. Do not follow generic advice to drink large amounts of water if another clinician has prescribed a fluid limit.

Ask what symptoms should prompt a call and whether kidney function needs monitoring. That is more useful than assuming that a normal test before treatment eliminates future risk.

Diabetes-related eye disease and insulin use

Diabetic retinopathy is damage to the retina related to diabetes. A history of this condition calls for review and appropriate eye follow-up, rather than automatic exclusion.

Changes in blood sugar can affect existing eye disease. Share your latest eye examination, any previous eye treatment, and any new vision symptoms so the prescriber can coordinate care where needed.

Insulin and certain diabetes medicines, including sulfonylureas, can increase the risk of low blood sugar when used with GLP-1-based treatment. This combination may still be appropriate, but medication adjustments and monitoring belong with the treating clinician.

GLP-1 medicines are not a substitute for insulin in type 1 diabetes. A person with type 1 diabetes who is considering a separate weight-management treatment needs coordinated assessment, not an independent reduction in insulin.

Eating disorders, poor nutrition, and mental health

Appetite suppression may be unsuitable when someone is already struggling to eat enough. Active restrictive eating, recurrent purging, significant unintentional weight loss, or malnutrition should be assessed before pursuing weight-loss medication.

An eating-disorder history deserves a conversation about current symptoms, recovery, and available support. The relevant question is how treatment could affect eating behavior and nutrition, not whether someone has demonstrated enough willpower.

Depression, anxiety, or a history of trauma should not be treated as an automatic class-wide contraindication. These conditions may influence the care plan, but an online list cannot determine treatment suitability from a diagnosis alone.

Tell the clinician if weight tracking, appetite changes, or dietary restriction has previously worsened your mental health. Nutrition support and eating-disorder care may be more urgent than choosing a weight-loss medicine.

Which medicines and procedures can affect suitability?

Other GLP-1 medicines and overlapping ingredients

Medication reconciliation means checking everything a person takes for duplication and interactions. It is especially important when care comes from more than one clinic.

Do not add a second GLP-1-based medicine or another product containing the same active ingredient on your own. Wegovy and Ozempic both contain semaglutide; Zepbound and Mounjaro both contain tirzepatide. Different brand names do not prevent overlapping exposure.

A switch between treatments requires a clinician’s plan. Leftover medication, a delayed delivery, or a weaker-than-expected appetite effect is not a reason to combine products.

Also list prescription pills, over-the-counter medicines, supplements, and injectable wellness products. Slower stomach emptying can matter for some oral medicines, while changes in food intake and health status may change monitoring needs. A pharmacist can help identify product-specific interactions without assuming that every oral medicine becomes ineffective.

Surgery, anesthesia, and deep sedation

GLP-1-based medicines can be relevant to procedures involving anesthesia or deep sedation because delayed stomach emptying may affect aspiration risk. Aspiration occurs when stomach contents enter the lungs.

An upcoming operation, endoscopy, or sedated procedure does not automatically mean someone can never use a GLP-1 medicine. It does mean the procedural team needs to know about it in advance.

Provide the exact medicine, formulation, last dose, recent treatment changes, and any nausea, vomiting, or prolonged fullness. The anesthesia and prescribing teams can then coordinate an individualized plan.

Do not apply a universal medication-holding rule found online. Withholding treatment can also have consequences, particularly for diabetes, and procedural instructions need to account for the specific situation.

Does choosing a compounded product change these limits?

A compounded preparation does not remove a medical reason to avoid its active ingredient. Adding a vitamin or changing the container does not establish that a product is safer for someone with a contraindication.

Compounded medicines are not FDA-approved. The FDA does not review their safety, effectiveness, and quality before marketing, and they should not be described as generic Wegovy, generic Zepbound, or clinically interchangeable alternatives. The FDA’s information on unapproved GLP-1 products explains these distinctions and related safety concerns.

When comparing compounded semaglutide with branded Wegovy, or compounded tirzepatide with branded Zepbound, medical suitability comes before convenience. A prescription does not by itself establish that every preparation is appropriate for a particular person.

Helimeds also provides separate compounded tirzepatide treatment information.

If a prescribed preparation comes in a vial, confirm the exact concentration and device instructions. Milligrams measure the amount of medicine, milliliters measure liquid volume, and syringe units are device markings. They are not interchangeable quantities.

The FDA’s compounded-semaglutide dosing-error alert describes errors associated with confusing measurements. Resolve unclear directions with the prescriber or dispensing pharmacist before injecting; do not calculate a dose from another person’s instructions.

When symptoms need help instead of another dose discussion

Nausea, diarrhea, vomiting, and constipation can occur during treatment. They are not proof that the medicine is working, and “common” does not mean that every episode is harmless.

For medication-specific detail, our guide to tirzepatide side effects discusses common symptoms and serious risks.

Persistent symptoms that interfere with eating, drinking, or daily activities deserve prompt contact with the treating clinician. Describe when they started, how severe they are, and whether they followed a treatment change. Do not independently increase the medicine while trying to push through significant symptoms.

Seek urgent medical assessment for:

• Severe or persistent abdominal pain, particularly with vomiting or pain extending toward the back.
• Upper abdominal pain with fever or yellowing of the skin or eyes.
• Repeated vomiting, inability to keep fluids down, markedly reduced urination, or significant dizziness.
• Sudden or substantial changes in vision.
• Symptoms of serious allergy, such as swelling of the face or throat or difficulty breathing.

Call 911 for difficulty breathing, collapse, seizure, loss of consciousness, or another immediate medical emergency. Customer support is not the appropriate destination for emergency symptoms.

Your initial eligibility assessment is only one part of safe treatment. New symptoms, pregnancy, new medicines, or an upcoming procedure can change the plan.

How to prepare for an eligibility conversation

A useful assessment connects the expected benefit to your actual health risks. Bring more than your current weight or a list of diagnoses.

Prepare the following information:

• The exact treatment you are considering or already taking, including brand, formulation, and pharmacy label.
• Your personal and family thyroid-cancer history, with the cancer type if known.
• Previous pancreatitis, gallstones, digestive disorders, kidney problems, and diabetes-related eye disease.
• All medicines and supplements, including insulin, diabetes pills, contraception, and other weight-management products.
• Pregnancy or breastfeeding plans, upcoming procedures, and any current trouble eating or drinking.
• Previous medication reactions, including what happened and whether treatment was needed.

Ask which findings are firm reasons to avoid the medicine, which require monitoring, and which need further evaluation. Also ask what alternatives make sense if a GLP-1-based medicine is unsuitable. Options may include nutrition care, another medication class, treatment of an underlying condition, or a specialist assessment.

If you choose to begin consultation through Helimeds, the pathway starts with a medical intake and review by an affiliated licensed clinician. A prescription is issued only if clinically appropriate and permitted in your state; a licensed pharmacy handles dispensing and fulfillment. Additional records, tests, a call, or in-person evaluation may be needed.

Conclusion

For Wegovy and Zepbound, MTC, MEN 2, and serious allergy to the intended product are clear reasons not to use the medicine. Pregnancy, severe gastroparesis, other health conditions, and medication interactions require additional distinctions rather than one blanket exclusion list.

Before beginning consultation, identify the exact product and gather the history that could change the decision. If you are already receiving treatment, bring new symptoms or changes in your health to the treating clinician rather than adjusting medication yourself. A safe plan may involve GLP-1 treatment, a different approach, or further evaluation first.

This article provides general health information and does not replace advice from your licensed healthcare professional.

Frequently asked questions

Can I take a GLP-1 medicine if I have hypothyroidism?

Hypothyroidism alone is not the same as medullary thyroid carcinoma or MEN 2, the conditions behind important contraindications for Wegovy and Zepbound. Your clinician should still review the cause of your thyroid condition and any thyroid medication you take. The exact GLP-1 formulation can matter when checking medication instructions and interactions.

Does a history of pancreatitis automatically rule out every GLP-1?

A previous episode requires careful assessment, but it should not be presented as a universal contraindication to every GLP-1 medicine. The cause, recurrence, current symptoms, and intended product matter. Bring records if available so the clinician can make a more informed decision.

Can people without diabetes take GLP-1-based weight-loss medicine?

Yes, certain products, including Wegovy and Zepbound, have approved weight-management uses that do not require diabetes. That does not mean everyone seeking weight loss is an appropriate candidate. A clinician must assess the product’s indication, expected benefit, contraindications, and individual risks.

If one GLP-1 causes side effects, does that mean I cannot take any?

Not necessarily; a troublesome side effect and a serious allergic reaction have different implications. The clinician needs the exact medicine, symptoms, timing, and severity before considering another option. Do not switch, combine treatments, or test a related medicine on your own.